tbuckley/cabot-search huggingface dataset:
False-Positive 131I Uptake in Fixed Prosthetic Denture
Authors: Cina Shin-Loong Tong, Tong Cina Shin-Loong, Ki Wang, Wang Ki, Sing-Fai Leung, Leung Sing-Fai
Journal: Clinical Nuclear Medicine (2012)

Iodine-131 whole-body scan is used to detect functional metastases in patients with history of differentiated thyroid carcinoma. Nonphysiological uptakes are usually interpreted as thyroid metastases. However, false-positive uptakes, such as nonthyroidal tumors and contamination from body secretions, have been reported. We report a case of incidental finding of tracer activity in a patient's prosthetic denture, which was localized by SPECT/CT. There is no evidence of dental or periodontal disease clinically or radiologically, and the serum thyroglobulin was at undetectable level. Potential false-positive activity related to dental conditions should be recognized and not be mistaken as metastatic disease.
FRI0210 What is the Prevalence of Mri-Detected Features in Small Joints in the General Population? A Literature Review
Authors: L. Mangnus, J.W. Schoones, A.H.M. van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> <i>Objectives</i>: MRI sensitively depicts erosions, bone marrow edema (BME), synovitis and tenosynovitis in rheumatoid arthritis (RA). Recently developed EULAR recommendations stated that MRI is valuable to improve the certainty of a considered diagnosis and to detect structural damage at an early time point. [1] These recommendations were based on data of patients; the prevalence of lesions in the general population was not extensively explored. We performed a literature review to study to what extend MRI lesions prevail in the general population. <h3>Methods</h3> <i>Methods</i>: Medical literature databases up to September 2013 were systematically reviewed for symptom-free persons with MRI data. Data were summarized and combined when allowed. <h3>Results</h3> <i>Results</i>: Of all screened 338 articles, 31 evaluated MRI-findings in symptom-free persons and in total 516 MRIs of symptom-free persons were evaluated. Both the imaging techniques and the scoring methods varied widely, prohibiting direct comparisons of the results of some studies. Fifteen studies scored data according to RAMRIS and showed erosions in 33-52% of symptom-free persons and bone marrow edema in 10-16%. Due to different protocols, data on synovitis and tenosynovitis could not be easily compared and the observed prevalence9s of synovitis ranged widely; synovitis was recorded in 0-82% of symptom-free persons. The prevalence of MRI-detected erosions increased with age, the same goes for BME. No differences were observed for gender or between dominant and non-dominant sites. <h3>Conclusions</h3> <i>Conclusions</i>: MRI lesions, erosions in particular, occur frequently in symptom free persons. This is important for the implementation of MRI in the diagnostic process. <h3>References</h3> Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013;:annrheumdis–2012–203158. doi:10.1136/annrheumdis-2012-203158 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4049
Abstract 2377: Aminopeptidase A plays a role in VEGF-induced migration and proliferation through direct activation by VEGFR2 kinase activity
Authors: Arend H. Sikkema, Eveline S. de Bont, Sander H. Diks, Arja ter Elst, Rob Ruijtenbeek, Piet J. Boender, Eelco W. Hoving, Willem A. Kamps, Wilfred F. den Dunnen, Maikel P. Peppelenbosch
Journal: Cancer Research (2010)

Abstract Tyrosine kinases pose attractive targets for cancer therapy, as their abnormal signaling activity results in enhanced proliferation, migration and angiogenesis. Previously we have been able to generate a comprehensive description of the biological kinase activity present in pediatric brain tumor tissue lysate by the application of a peptide microarray containing 144 different tyrosine kinase peptide substrates. To establish which peptide substrates present on the array are most sensitive and discriminative for VEGFR activity we measured the peptide phosphorylation applying recombinant VEGFR1, 2 and 3. Furthermore, a panel of recombinant kinases with highly diverse VEGFR sequence homology was included to study substrate specificity. An aminopeptidase A (APA) derived peptide proved to be highly phosphorylated by VEGFR 1 and 2. No phosphorylation of this peptide could be observed applying any of the other kinases, arguing that this peptide is discriminative for VEGFR1 and 2 activity. In the peptide array data of pediatric brain tumors, phosphorylation of the APA peptide was observed, suggestive for VEGFR activation. Based on these results we hypothesize that APA can be activated through direct phosphorylation by VEGFR2 and exert functional effects on endothelial cell proliferation and migration. To test this hypothesis we stimulated human umbilical vein endothelial cells (HUVECs) with VEGF and observed phosphorylation of Aminopeptidase A. Literature states that inhibition of APA suppresses VEGF-induced migration and proliferation of endothelial cells and inhibits angiogenesis. Based on our data we hypothesize that these APA-mediated effects of VEGF stimulation are induced through direct activation by VEGFR2 kinase activity. Concluding, peptide microarray technology is able to provide a selective view on tyrosine kinase activation, as has been shown here for VEGFR1 and 2. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2377.
Eosinophil Granule Protein Localization in Eosinophilic Endomyocardial Disease
Authors: Benjamin L. Wright, Kristin M. Leiferman, Gerald J. Gleich
Journal: New England Journal of Medicine (2011)

In this case report, eosinophilic endomyocardial disease was diagnosed in a patient on the basis of immunohistochemical evidence of eosinophil granule protein deposition in the heart, even in the absence of eosinophilic infiltration on cardiac biopsy.
DISECCION ENDOSCOPICA SUBMUCOSA EN UN HOSPITAL ESPAÑOL. ¿HAY LUGAR PARA LA ESPERANZA?
Authors: J De La Peña García, Á Terán Lantarón, PL Fernández Gil, P Iruzubieta Coz, D Hernández Amunarriz, MJ Garcia Garcia, J Cabezas Delgado
Journal: Endoscopy (2013)

Introducción: La disección endoscópica submucosa (DES) es una técnica avanzada de endoscopia terapéutica, con alta tasa de éxito en resección curativa de tumores digestivos superficiales, pero con alta tasa de complicaciones. Objetivo: Analizar y comparar los resultados de nuestra serie de DES con las series publicadas hasta ahora. Material y Método: se elevó la lesión con ácido hialurónico y se realizó una incisión circunferencial y disección submucosa con disectotómos convencionales o hidrodisector. Se registraron prospectivamente las características clínicas de los pacientes, complicaciones, resultados anatomopatológicos y clínico-endoscópicos a los 3 y cada 12 meses. Resultados: Se han practicado 27 DES (11 estómago, 14 colon), con un seguimiento medio de 20 meses (1 – 84); 12 resultaron carcinomas, 13 pólipos benignos y 2 tumores del estroma. La resección en una pieza (R0) se consiguió en 16 casos y en fragmentos en 11, pero el porcentaje de R0 fue del 80% en el último tercio de resecciones. Resección completa se logró en el 85% de los casos y no precisó de nuevas terapias en el 70% de los casos. Se registraron 3 hemorragias (11%) (dos precisaron tratamiento endoscópico) y 4 perforaciones (15%) (2 tratamiento endoscópico y 2 quirúrgico) sin mortalidad. Tres casos precisaron cirugía por resección incompleta o tumor avanzado. Fallecieron 7 pacientes a los 6 – 24 meses de enfermedades sin relación con la tumoración y 16 sobreviven sin evidencia de tumor y sin precisar otro tratamiento adicional en la actualidad. La introducción del hidrodisector es un factor claro de mejora con R0 en 6 de 9 casos, resección completa en 100% y solo una hemorragia digestiva.
Abstract 4467: Role of 12-lipoxygenase in regulation of ovarian cancer growth
Authors: Austin M. Guo, Zaid Al-Wahab, Xiuli Liu, Krishna Rao Maddippadi, Rouba Ali, A. Guillermo Scicli, Adnan Munkarah
Journal: Cancer Research (2011)

Abstract Eicosanoid-related enzymes may be implicated in the pathogenesis of ovarian cancer. We found that high grade serous ovarian carcinoma had a significantly higher level of 12-LOX expression than normal ovarian epithelium. These data led us to hypothesize that the lipoxygenase pathway is important in the regulation of ovarian cancer growth. In the present study, we examined the role of 12-lipoxygenase (12-LOX), the main human 12-HETE generating enzyme, in the regulation of proliferation and survival in epithelial ovarian cancer in vitro and ovarian cancer development and angiogenesis in vivo. Down-regulation of the 12-LOX expression using 12-LOX siRNA also resulted in markedly reduction in the epithelial ovarian cancer (EOC) OVCAR-3 growth as we have previously observed with BMD-122, a selective 12-LOX inhibitor. In addition, BMD-122 significant inhibited the VEGF expression whereas purified 12-HETE increase VEGF expression in OVCAR-3 cells. Furthermore, we found that BMD-122 markedly decreases angiogenesis induced by OVCAR-3 in a Matrigel plug angiogenesis assay. Systemic administration of BMD-122 to nude mice bearing experimentally-induced ovarian cancer resulted in a 60 % decrease in tumor size. These data suggest that 12-LOX may be involved in regulation of ovarian cancer growth, survival and cancer-induced angiogenesis. Thus inhibition of 12-LOX could be useful as adjuvant therapy of ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4467. doi:10.1158/1538-7445.AM2011-4467
Court Test of Tissue Ownership Leaves Uncertainty About Impact
Authors: H. McIntosh
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Court Test of Tissue Ownership Leaves Uncertainty About Impact Get access Hugh McIntosh Hugh McIntosh Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 16, 19 October 1988, Pages 1270–1272, https://doi.org/10.1093/jnci/80.16.1270 Published: 19 October 1988
Isolated Gonadotropin Deficiency with Response to Luteinizing-Hormone-Releasing Hormone
Authors: Takuma Hashimoto, Kiyoshi Miyai, Kanji Izumi, Yuichi Kumahara
Journal: New England Journal of Medicine (1972)

Abstract A 27-year-old man (chromosomes 46 XY) with  was not anosmic, and his body build was eunuchoid. Testicular biopsy demonstrated arrested spermatogenesis and Leydig-cell atrophy. Growth hormone, adrenocorticotropin, and thyrotropin responses were found to be intact. Serum follicle-stimulating hormone and luteinizing hormone concentrations, as determined by radioimmunoassay, were undetectable and did not increase after administration of clomiphene citrate. However, the administration of synthetic luteinizing-hormone-releasing hormone increased serum luteinizing hormone and follicle-stimulating hormone concentrations respectively to 22 and 4.1 mIU per milliliter. Our patient thus has a condition for which the term hypothalamic (or tertiary) hypogonadism may be appropriate.
PTU-181 An exploratory qualitative study investigating patients’ experiences of constipation and how their self-reported symptoms and quality of life compare with currently available validated measures
Authors: E Dimidi, L Dibley, N Cotterill, CH Knowles, SM Scott, K Whelan, C Norton
Journal: Gut (2015)

<h3>Introduction</h3> The most widely-used validated questionnaires for assessing constipation are the Patient Assessment of Constipation Symptoms (PAC-SYM) and the Cleveland Clinic Constipation Score (CCCS). We aimed to assess patients’ reported symptoms of constipation, preferred terminology, and quality of life (QoL) issues, and whether these are reflected in currently available validated questionnaires. <h3>Method</h3> Nineteen semi-structured interviews were conducted with patients presenting with constipation to assess their symptoms, the terminology they preferred, suitability of existing assessment tools, and to explore participants’ constipation-related QoL issues. An inductive thematic framework was adopted to identify subthemes. Eleven clinicians rated the clinical importance of the symptoms and QoL issues reported by patients. <h3>Results</h3> Three main themes were identified: a) language used to describe bowel issues, b) symptoms and toilet behaviours and c) issues regarding QoL. <i>“Stool”</i>and <i>“motions”</i>were the most acceptable words to describe stool, and <i>“going to the toilet”</i>for describing the act of defecation. The words <i>“digital assistance”, “evacuation”</i>and <i>“defecation”</i>were poorly understood. Of the 12 most troublesome symptoms patients reported, only four are included in the PAC-SYM and five in the CCCS. Six of the symptoms reported as most troublesome are not included in either the PAC-SYM or the CCCS. Although all clinicians reported uncontrolled leakage of stool as a clinically important symptom, this was not included in either assessment tool. Of the symptoms that clinicians thought to be the most clinically relevant, two were not reported to be bothersome by patients (use of laxatives, straining). Only a small number of clinicians perceived some of the most bothersome symptoms reported by patients as clinically relevant. <h3>Conclusion</h3> Patients presenting with constipation report a range of individual symptoms and QoL issues, most of which are not included in validated questionnaires. The terminology used in these questionnaires for describing bowel issues is poorly understood by patients. Furthermore, there is a discrepancy between patients and clinicians on what symptoms and QoL issues are perceived to be important. The development of a new assessment tool evaluating the wide range of constipation-related symptoms and QoL issues is needed. <h3>Disclosure of interest</h3> E. Dimidi: None Declared, L. Dibley: None Declared, N. Cotterill Consultant for: Astellas Pharma Europe B. V. and Procter and Gamble, C. Knowles: None Declared, S. Scott: None Declared, K. Whelan: None Declared, C. Norton: None Declared.
SAT0225 Do Bone Marrow Edema (BME) Lesions in the Sacroiliac Joint (SIJ) Change into Fatty Lesions Over A 3-Month Period in Patients with Axial Spondyloarthritis (AXSPA)?
Authors: M. De Hooge, R. Van Den Berg, M. V. Navarro Compán, M. Reijnierse, F. van Gaalen, K. M. Fagerli, R. Landewé, M. van Oosterhout, R. Ramonda, T. Huizinga, D. Van Der Heijde
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> BME lesions may change into fatty lesions in the SIJ over time. In one study significant changes of fatty lesions in the SI joints were observed over 1 year in patients (pts) with axSpA<sup>1</sup>. Are similar results found with a shorter follow-up period? <h3>Objectives</h3> To investigate whether BME lesions in the SIJ seen on MRI change into fatty lesions over a 3-month period in pts with axSpA. <h3>Methods</h3> Pts with back pain (≥3 months, ≤2 years, onset &lt;45 years) from the 5 participating centres of the SPondyloArthritis Caught Early (SPACE)-cohort were included. All pts fulfilling the ASAS axSpA criteria underwent MRI-SI at baseline (MRI-SI-B) and after 3 months (MRI-SI-3m). MRI-SI-B and MRI-SI-3m were scored by 2 well-calibrated readers independently, blinded for time point, for the presence of BME and fatty lesions on STIR and MRI T1-weighted images viewed simultaneously. BME and fatty lesions were defined present if 1 lesion on ≥2 consecutive slices or &gt;1 lesion on a single slice. The scores of baseline and 3 months were compared on quadrant level (Q) and sum of all quadrants (8 total) to obtain pt score. Scores of the readers are reported separately. <h3>Results</h3> Only axSpA pts with MRI-SI-B and MRI-SI-3m were included for this analysis (n=83, number of Q=664). In 62/83 pts (74.7%) reader 1 indicated the presence of BME or fatty lesions at any time point, reader 2 indicated this in 60/83 pts (72.3%). Readers agreed in 73/83 pts (88%) on the presence of lesions at any time point. Reader 1 indicated no lesions at baseline or follow-up in 410/664 Qs (61.7%) and in 131/664 Qs (19.7%) the type of lesions did not change over time. In 123/664 Qs (18.5%) lesions occurred, disappeared or changed from one type to another. In total, there were 34/664 Qs (5.1%) in which fatty lesions occurred, and 29/664 Qs (4.4%) in which fatty lesions disappeared. In only 3/664 Qs (0.5%) BME lesions on MRI-SI-B turned into FAT lesions at MRI-SI-3m. In the same amount of Qs the opposite thing is happening; FAT lesions change into BME lesions over time. The results of both readers show similar trends (see table). <h3>Conclusions</h3> We find a lot of volatility of BME and fatty lesions over 3 months time. It is common for both lesions to occur without a previous lesion or disappear completely without leaving a mark, but it is uncommon to see BME lesions turn into fatty lesions over a period of 3 months. This observation casts serious doubts on the value of fatty lesions as a surrogate for previous inflammation. <h3>References</h3> Song ARD 2011;70:1257-63 <h3>Disclosure of Interest</h3> None Declared
The Diagnosis and Management of Biliary-Tract Disease
Authors: Robert M. Zollinger, E. Thomas Boles, Glenn B. Crawford
Journal: New England Journal of Medicine (1955)

THERE have been few fundamental contributions to the diagnosis and management of biliary-tract disease in recent years, but a current evaluation of the subject is justified in view of the large number of cholecystectomies being performed today and the frequency of complications of biliary-tract disease in patients seen by the surgeon for the first time. Cholecystectomy has become a common major abdominal operation, ranking approximately fourth after the triad of appendectomy, herniorrhaphy and hysterectomy. Although the operation is common, and the immediate morbidity and mortality are quite low, many patients tend to question the physician's recommendation for biliary-tract surgery. Even . . .
Increased Pertechnegas Lung Clearance in Interstitial Lung Disease
Authors: BILL MOURATIDIS, JOE LISING, STEPHEN NOGRADY, MARK HURWITZ
Journal: Clinical Nuclear Medicine (1999)

Background: Interstitial lung disease (ILD) is characterized by inflammation within the alveolar walls and interstitium of the lungs. This causes increased alveolar-capillary membrane permeability. The diagnosis is made by clinical features, chest roentgenography, lung function tests, and high-resolution CT, and it is confirmed by lung biopsy. Radionuclide aerosol tracers such as Tc-99m DTPA show increased lung clearance in ILD. The clearance rate of microaerosol pertechnegas (modified Technegas) from the lungs in the assessment of ILD was evaluated. Methods: Thirty-two patients (22 with ILD and 10 with non-ILD) were evaluated with pertechnegas. Pertechnegas is formed by adding 3% oxygen to technegas, a microaerosol ventilation agent. Regions of interest were then drawn around the lungs, and clearance rates were determined from the best exponential fit. Results: The mean clearance rate of pertechnegas was significantly increased in ILD and measured 5.78 ± 2.2 minutes compared with non-ILD, which measured 8.53 ± 2.42 minutes (P < 0.001). The sensitivity and specificity rates of pertechnegas clearance (less than 8 minutes) in ILD were 90% and 60%, respectively. When combined with chest roentgenography, the sensitivity and specificity rates increased to 100% and 90%, respectively. Conclusions: Pertechnegas is highly effective in determining the presence of active ILD. It differentiates between active ILD and non-ILD, and it is highly sensitive and specific when combined with chest roentgenography. Its potential role in the management of ILD merits further investigation.
Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants
Authors: Yitzhak Zimmer, Benoît Pochon, Deborah M. Stroka, Daniel M. Aebersold, Andree Blaukat, Friedhelm Bladt, Michaela Medová
Journal: Cancer Research (2012)

Abstract The receptor tyrosine kinase MET is a prime target in clinical oncology because of its aberrant activation in a broad spectrum of malignancies. Here, we tested the anti tumor activity of a novel MET inhibitor, EMD1214063, on cancer cells overexpressing MET and in eight transfected NIH3T3 cell lines expressing different activating mutants of the MET kinase. Our results demonstrate a dose-dependent decrease in MET autophosphorylation in both MET overexpressing cell lines (IC50 of 20nM and 30nM for GTL-16 and H1993, respectively) and in six of the eight cell lines transfected with MET activating mutants (IC50 5-18nM). Blockade of MET by EMD1214063 resulted in reduced downstream activation of AKT, ERK and PLCγ. In contrast, lack of MET inhibition by EMD1214063 in the resistant Y1248H and L1213V MET mutants was associated with high levels of AKT, ERK and PLCγ activation. In all sensitive mutants, EMD1214063 attenuated MET-dependent cellular proliferation and significantly altered cell cycle distribution profiles (increase in G1 and concomitant decrease of S phase). Furthermore, EMD1214063 strongly affected MET-driven biological functions, such as cellular morphology, motility and anchorage-independent growth. To assess the in vivo efficacy of EMD1214063, we established tumor transplantation models exploiting NIH3T3 cells expressing the H1112L or L1213V MET mutants, respectively sensitive and resistant, to in vitro treatment with EMD1214063. Animals bearing H1112L or L1213V tumors were randomized for the treatment with EMD1214063 (50mg/kg/day) or vehicle only. Remarkably, 5 days of treatment with EMD1214063 induced complete regression of sensitive H1112L tumors, while tumor growth remained unaffected in mice injected with resistant L1213V tumor cells and in vehicle-treated mice. Taken together, these results underscore the concordance between in vitro and in vivo effects of EMD1214063 and strongly support its efficacy in inhibiting MET-driven tumor cell growth. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1786. doi:1538-7445.AM2012-1786